Verition Fund Management’s Maravai LifeSciences MRVI Stock Holding History

Verition Fund Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-60,037	Closed	-$430K	–	3408
2024 Q2	$430K	Buy	+60,037	New	+$518K	﹤0.01%	2138
2023 Q3	–	Sell	-153,946	Closed	-$1.91M	–	2554
2023 Q2	$1.91M	Buy	153,946 +139,955	+1,000%	+$1.89M	0.03%	689
2023 Q1	$196K	Sell	13,991 -8,892	-39%	-$128K	﹤0.01%	1776
2022 Q4	$327K	Buy	+22,883	New	+$360K	0.01%	1452
2022 Q3	–	Sell	-32,244	Closed	-$916K	–	3164
2022 Q2	$916K	Buy	32,244 +6,020	+23%	+$191K	0.02%	1078
2022 Q1	$925K	Buy	+26,224	New	+$879K	0.01%	1522
2021 Q3	–	Sell	-5,850	Closed	-$244K	–	2173
2021 Q2	$244K	Buy	+5,850	New	+$227K	﹤0.01%	1459

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Verition Fund Management's MRVI Position: Q3 2024 in Review

Verition Fund Management sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 60,037 shares — an estimated $430K sold.

Verition Fund Management first reported a position in MRVI in Q2 2021 and held it in 7 quarters. The position peaked at $1.91M in Q2 2023. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Verition Fund Management reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Verition Fund Management sold 60,037 Maravai LifeSciences shares in Q3 2024, an estimated $430K.
Verition Fund Management first reported a position in Maravai LifeSciences in Q2 2021 and held it in 7 quarters.
Verition Fund Management's Maravai LifeSciences position peaked at $1.91M in Q2 2023.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.